10 Best Penny Stocks to Buy for Long Term
The opportunity is not in buying every low-priced penny stock but rather in finding smaller companies where earnings, balance sheets, and business quality are improving faster than the market is giving...
Abcellera Biologics Inc. (ABCL)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 30,275,938 | $105,663,024 | +10% | 0.61% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 10,562,065 | $36,861,607 | +117% | 0.03% |
| 3. | Driehaus Capital Richard Driehaus | 4,024,779 | $14,046,479 | +7% | 0.1% |
| 4. | Leucadia National Ian Cumming And Joseph Steinberg | 2,746,200 | $9,584,238 | 0.07% | |
| 5. | 2,736,200 | $9,549,338 | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.77 | 20,000 | $95,400.00 | 241,000 | 2026-05-14 | Filing | |
| $3.44 | 38,000 | $130,720.00 | 56,134,097 | 2026-02-27 | Filing | |
| $3.27 | 177,457 | $580,284.39 | 56,096,097 | 2026-02-26 | Filing | |
| $3.42 | 42,600 | $145,692.00 | 195,600 | 2026-02-27 | Filing | |
| $3.57 | 50,000 | $178,460.00 | 221,000 | 2025-11-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.93 | 137,351 | $2,325,352.43 | 128,862 | 2021-09-01 | Filing | |
| $16.95 | 162,649 | $2,756,900.55 | 266,213 | 2021-08-31 | Filing | |
| $25.50 | 100,000 | $2,550,000.00 | 1,003,397 | 2021-06-22 | Filing | |
| $24.03 | 5,598,420 | $134,530,032.60 | 55,604,330 | 2021-06-09 | Filing | |
| $25.50 | 401,580 | $10,240,290.00 | 233,500 | 2021-06-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,361,096 | $46,630,225 | 0.01% | |
| 2. | 9,564,659 | $33,569,696 | 0.1% | |
| 3. | 7,575,476 | $26,438,411 | 0.01% | |
| 4. | 4,209,052 | $14,689,591 | 0% | |
| 5. | 4,105,095 | $14,326,782 | 0.38% |
News See All
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, and welcome to AbCellera's Q1 2026 Business Update Conference Call. My name is Ben, and I will facilitate the audio portion of today's interactive broadcast.
8 Best Healthcare AI Stocks to Buy According to Analysts
Healthcare AI stocks are getting more attention as investors look for places where artificial intelligence can move beyond chatbots and productivity tools into real-world markets.
JonesResearch Initiates Coverage of AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best stocks under $5 with huge upside potential. On April 9, JonesResearch initiated coverage of AbCellera Biologics Inc.
10 Stocks Under $5 with Huge Upside Potential
He cited the breadth of the market, stating that it's not just the Mag 7 or tech, but also the S&P, the Dow, the Nasdaq, and even the Russell that is moving higher.
8 Best Life Sciences Penny Stocks to Buy
On March 11, CBRE shared an analysis covering the U.S. market trends in life sciences real estate.
10 Stocks That Could 10X Over the Next 5 Years
March appears to be finishing on a low note, with the S&P 500 dipping on March 30, pulled down by new rises in oil prices and a sharp decline in technology, as traders moved on from Fed Chair Jerome Powell...
AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the most promising penny stocks under $5 to buy.
AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to AbCellera's Full Year 2025 Business Update Conference Call. My name is Chelsea, and I will facilitate the audio portion of today's interactive broadcast.
13 Most Promising Penny Stocks Under $5 to Buy
On February 23, Pierre Ouimet, head investment strategist at UBS Canada, joined BNN Bloomberg to discuss the markets and provide a spotlight on undervalued sectors.
Hedge Fund Resource Center